Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma

Japan Clinical Oncology Group study 9004

Kensei Tobinai, Kunihiko Takeyama, Fumito Arima, Keiko Aikawa, Tohru Kobayashi, Shuichi Hanada, Masaharu Kasai, Michinori Ogura, Eisaburo Sueoka, Kiyoshi Mukai, Kinuko Tajima, Haruhiko Fukuda, Shigeru Shirakawa, Tomomitsu Hotta, Masanori Shimoyama, C. Mikuni, K. AIkawa, M. Kasai, Y. Kiyama, I. Miura & 56 others A. Miura, T. Sai, Y. Sasaki, K. Itoh, M. Shimoyama, K. Tobinai, K. Minato, T. Takenaka, K. Takeyama, A. Kohno, U. Sawada, I. Aoki, K. Kawano, T. Ibuka, T. Miwa, A. Togawa, H. Yamada, S. Iwase, K. Deura, S. Seki, M. Ogura, Y. Kagami, H. Suzuki, H. Nagai, T. Hotta, T. Kinoshita, M. Hirano, M. Okamoto, S. Shirakawa, T. Kobayashi, M. Masuya, M. Yamaguchi, S. Konda, Y. Masaki, T. Susuki, S. Fukuhara, H. Ohno, T. Abe, M. Taniwaki, Y. Ohno, S. Irino, M. Nagai, N. Uike, Shinichiro Okamoto, K. Fujita, Y. Izumi, Y. Shimamoto, H. Fukushima, K. Yamaguchi, K. Takatsuki, M. Matsumoto, S. Hanada, K. Uozumi, A. Utsunomiya, K. Araki, I. Ohshiro

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Granulocyte colony-stimulating factor (G-CSF)-supported, post-remission chemotherapy (Cx) for adult acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) was evaluated. One hundred and forty-three eligible patients (median age, 41years) including 126 ALL and 17 LBL receiving induction Cx (vincristine, cyclophosphamide, prednisolone [PSL], doxorubicin, L-asparaginase, intrathecal-methotrexate [IT-MTX]) were analyzed. For patients achieving complete response (CR), two courses of post-remission Cx (course A of daunorubicin, cytosine arabinoside, vindesine, PSL plus IT-MTX; course B of mitoxantrone, etoposide, vincristine, PSL plus IT-MTX) with the use of G-CSF were repeated alternately; thereafter, maintenance Cx including MTX and 6-mercaptopurine was given for 2 years. One hundred and nineteen (83%) patients achieved CR, while 14 (10%) died during induction. Among the 119 patients achieving CR, five died in remission, 76 relapsed, and the remaining 38 were alive without disease. The median survival time of the 143 eligible patients was 26 months (95% confidence interval, 19-34). At a median follow-up time of 9 years, the 5-year survival rate was 32% and the 5-year progression-free survival (PFS) rate was 26%. The 5-year survival rate of 36 patients who underwent autologous (n = 20) or allogeneic stem cell transplantation (SCT; n = 16) in the first CR group was 58%. Compared with the authors' previous trials, survival and PFS were markedly improved. In conclusion, G-CSF-supported, intensive post-remission Cx and subsequent SCT are worthy of further investigation for the treatment of adult ALL and LBL.

Original languageEnglish
Pages (from-to)1350-1357
Number of pages8
JournalCancer Science
Volume98
Issue number9
DOIs
Publication statusPublished - 2007 Sep
Externally publishedYes

Fingerprint

Medical Oncology
Stem Cell Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Japan
Drug Therapy
Granulocyte Colony-Stimulating Factor
Prednisolone
Methotrexate
Survival Rate
Vincristine
Disease-Free Survival
Vindesine
Asparaginase
6-Mercaptopurine
Mitoxantrone
Daunorubicin
Survival
Cytarabine
Etoposide
Doxorubicin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma : Japan Clinical Oncology Group study 9004. / Tobinai, Kensei; Takeyama, Kunihiko; Arima, Fumito; Aikawa, Keiko; Kobayashi, Tohru; Hanada, Shuichi; Kasai, Masaharu; Ogura, Michinori; Sueoka, Eisaburo; Mukai, Kiyoshi; Tajima, Kinuko; Fukuda, Haruhiko; Shirakawa, Shigeru; Hotta, Tomomitsu; Shimoyama, Masanori; Mikuni, C.; AIkawa, K.; Kasai, M.; Kiyama, Y.; Miura, I.; Miura, A.; Sai, T.; Sasaki, Y.; Itoh, K.; Shimoyama, M.; Tobinai, K.; Minato, K.; Takenaka, T.; Takeyama, K.; Kohno, A.; Sawada, U.; Aoki, I.; Kawano, K.; Ibuka, T.; Miwa, T.; Togawa, A.; Yamada, H.; Iwase, S.; Deura, K.; Seki, S.; Ogura, M.; Kagami, Y.; Suzuki, H.; Nagai, H.; Hotta, T.; Kinoshita, T.; Hirano, M.; Okamoto, M.; Shirakawa, S.; Kobayashi, T.; Masuya, M.; Yamaguchi, M.; Konda, S.; Masaki, Y.; Susuki, T.; Fukuhara, S.; Ohno, H.; Abe, T.; Taniwaki, M.; Ohno, Y.; Irino, S.; Nagai, M.; Uike, N.; Okamoto, Shinichiro; Fujita, K.; Izumi, Y.; Shimamoto, Y.; Fukushima, H.; Yamaguchi, K.; Takatsuki, K.; Matsumoto, M.; Hanada, S.; Uozumi, K.; Utsunomiya, A.; Araki, K.; Ohshiro, I.

In: Cancer Science, Vol. 98, No. 9, 09.2007, p. 1350-1357.

Research output: Contribution to journalArticle

Tobinai, K, Takeyama, K, Arima, F, Aikawa, K, Kobayashi, T, Hanada, S, Kasai, M, Ogura, M, Sueoka, E, Mukai, K, Tajima, K, Fukuda, H, Shirakawa, S, Hotta, T, Shimoyama, M, Mikuni, C, AIkawa, K, Kasai, M, Kiyama, Y, Miura, I, Miura, A, Sai, T, Sasaki, Y, Itoh, K, Shimoyama, M, Tobinai, K, Minato, K, Takenaka, T, Takeyama, K, Kohno, A, Sawada, U, Aoki, I, Kawano, K, Ibuka, T, Miwa, T, Togawa, A, Yamada, H, Iwase, S, Deura, K, Seki, S, Ogura, M, Kagami, Y, Suzuki, H, Nagai, H, Hotta, T, Kinoshita, T, Hirano, M, Okamoto, M, Shirakawa, S, Kobayashi, T, Masuya, M, Yamaguchi, M, Konda, S, Masaki, Y, Susuki, T, Fukuhara, S, Ohno, H, Abe, T, Taniwaki, M, Ohno, Y, Irino, S, Nagai, M, Uike, N, Okamoto, S, Fujita, K, Izumi, Y, Shimamoto, Y, Fukushima, H, Yamaguchi, K, Takatsuki, K, Matsumoto, M, Hanada, S, Uozumi, K, Utsunomiya, A, Araki, K & Ohshiro, I 2007, 'Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group study 9004', Cancer Science, vol. 98, no. 9, pp. 1350-1357. https://doi.org/10.1111/j.1349-7006.2007.00556.x
Tobinai, Kensei ; Takeyama, Kunihiko ; Arima, Fumito ; Aikawa, Keiko ; Kobayashi, Tohru ; Hanada, Shuichi ; Kasai, Masaharu ; Ogura, Michinori ; Sueoka, Eisaburo ; Mukai, Kiyoshi ; Tajima, Kinuko ; Fukuda, Haruhiko ; Shirakawa, Shigeru ; Hotta, Tomomitsu ; Shimoyama, Masanori ; Mikuni, C. ; AIkawa, K. ; Kasai, M. ; Kiyama, Y. ; Miura, I. ; Miura, A. ; Sai, T. ; Sasaki, Y. ; Itoh, K. ; Shimoyama, M. ; Tobinai, K. ; Minato, K. ; Takenaka, T. ; Takeyama, K. ; Kohno, A. ; Sawada, U. ; Aoki, I. ; Kawano, K. ; Ibuka, T. ; Miwa, T. ; Togawa, A. ; Yamada, H. ; Iwase, S. ; Deura, K. ; Seki, S. ; Ogura, M. ; Kagami, Y. ; Suzuki, H. ; Nagai, H. ; Hotta, T. ; Kinoshita, T. ; Hirano, M. ; Okamoto, M. ; Shirakawa, S. ; Kobayashi, T. ; Masuya, M. ; Yamaguchi, M. ; Konda, S. ; Masaki, Y. ; Susuki, T. ; Fukuhara, S. ; Ohno, H. ; Abe, T. ; Taniwaki, M. ; Ohno, Y. ; Irino, S. ; Nagai, M. ; Uike, N. ; Okamoto, Shinichiro ; Fujita, K. ; Izumi, Y. ; Shimamoto, Y. ; Fukushima, H. ; Yamaguchi, K. ; Takatsuki, K. ; Matsumoto, M. ; Hanada, S. ; Uozumi, K. ; Utsunomiya, A. ; Araki, K. ; Ohshiro, I. / Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma : Japan Clinical Oncology Group study 9004. In: Cancer Science. 2007 ; Vol. 98, No. 9. pp. 1350-1357.
@article{e532ae010deb4fe795f6134d03699836,
title = "Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group study 9004",
abstract = "Granulocyte colony-stimulating factor (G-CSF)-supported, post-remission chemotherapy (Cx) for adult acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) was evaluated. One hundred and forty-three eligible patients (median age, 41years) including 126 ALL and 17 LBL receiving induction Cx (vincristine, cyclophosphamide, prednisolone [PSL], doxorubicin, L-asparaginase, intrathecal-methotrexate [IT-MTX]) were analyzed. For patients achieving complete response (CR), two courses of post-remission Cx (course A of daunorubicin, cytosine arabinoside, vindesine, PSL plus IT-MTX; course B of mitoxantrone, etoposide, vincristine, PSL plus IT-MTX) with the use of G-CSF were repeated alternately; thereafter, maintenance Cx including MTX and 6-mercaptopurine was given for 2 years. One hundred and nineteen (83{\%}) patients achieved CR, while 14 (10{\%}) died during induction. Among the 119 patients achieving CR, five died in remission, 76 relapsed, and the remaining 38 were alive without disease. The median survival time of the 143 eligible patients was 26 months (95{\%} confidence interval, 19-34). At a median follow-up time of 9 years, the 5-year survival rate was 32{\%} and the 5-year progression-free survival (PFS) rate was 26{\%}. The 5-year survival rate of 36 patients who underwent autologous (n = 20) or allogeneic stem cell transplantation (SCT; n = 16) in the first CR group was 58{\%}. Compared with the authors' previous trials, survival and PFS were markedly improved. In conclusion, G-CSF-supported, intensive post-remission Cx and subsequent SCT are worthy of further investigation for the treatment of adult ALL and LBL.",
author = "Kensei Tobinai and Kunihiko Takeyama and Fumito Arima and Keiko Aikawa and Tohru Kobayashi and Shuichi Hanada and Masaharu Kasai and Michinori Ogura and Eisaburo Sueoka and Kiyoshi Mukai and Kinuko Tajima and Haruhiko Fukuda and Shigeru Shirakawa and Tomomitsu Hotta and Masanori Shimoyama and C. Mikuni and K. AIkawa and M. Kasai and Y. Kiyama and I. Miura and A. Miura and T. Sai and Y. Sasaki and K. Itoh and M. Shimoyama and K. Tobinai and K. Minato and T. Takenaka and K. Takeyama and A. Kohno and U. Sawada and I. Aoki and K. Kawano and T. Ibuka and T. Miwa and A. Togawa and H. Yamada and S. Iwase and K. Deura and S. Seki and M. Ogura and Y. Kagami and H. Suzuki and H. Nagai and T. Hotta and T. Kinoshita and M. Hirano and M. Okamoto and S. Shirakawa and T. Kobayashi and M. Masuya and M. Yamaguchi and S. Konda and Y. Masaki and T. Susuki and S. Fukuhara and H. Ohno and T. Abe and M. Taniwaki and Y. Ohno and S. Irino and M. Nagai and N. Uike and Shinichiro Okamoto and K. Fujita and Y. Izumi and Y. Shimamoto and H. Fukushima and K. Yamaguchi and K. Takatsuki and M. Matsumoto and S. Hanada and K. Uozumi and A. Utsunomiya and K. Araki and I. Ohshiro",
year = "2007",
month = "9",
doi = "10.1111/j.1349-7006.2007.00556.x",
language = "English",
volume = "98",
pages = "1350--1357",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma

T2 - Japan Clinical Oncology Group study 9004

AU - Tobinai, Kensei

AU - Takeyama, Kunihiko

AU - Arima, Fumito

AU - Aikawa, Keiko

AU - Kobayashi, Tohru

AU - Hanada, Shuichi

AU - Kasai, Masaharu

AU - Ogura, Michinori

AU - Sueoka, Eisaburo

AU - Mukai, Kiyoshi

AU - Tajima, Kinuko

AU - Fukuda, Haruhiko

AU - Shirakawa, Shigeru

AU - Hotta, Tomomitsu

AU - Shimoyama, Masanori

AU - Mikuni, C.

AU - AIkawa, K.

AU - Kasai, M.

AU - Kiyama, Y.

AU - Miura, I.

AU - Miura, A.

AU - Sai, T.

AU - Sasaki, Y.

AU - Itoh, K.

AU - Shimoyama, M.

AU - Tobinai, K.

AU - Minato, K.

AU - Takenaka, T.

AU - Takeyama, K.

AU - Kohno, A.

AU - Sawada, U.

AU - Aoki, I.

AU - Kawano, K.

AU - Ibuka, T.

AU - Miwa, T.

AU - Togawa, A.

AU - Yamada, H.

AU - Iwase, S.

AU - Deura, K.

AU - Seki, S.

AU - Ogura, M.

AU - Kagami, Y.

AU - Suzuki, H.

AU - Nagai, H.

AU - Hotta, T.

AU - Kinoshita, T.

AU - Hirano, M.

AU - Okamoto, M.

AU - Shirakawa, S.

AU - Kobayashi, T.

AU - Masuya, M.

AU - Yamaguchi, M.

AU - Konda, S.

AU - Masaki, Y.

AU - Susuki, T.

AU - Fukuhara, S.

AU - Ohno, H.

AU - Abe, T.

AU - Taniwaki, M.

AU - Ohno, Y.

AU - Irino, S.

AU - Nagai, M.

AU - Uike, N.

AU - Okamoto, Shinichiro

AU - Fujita, K.

AU - Izumi, Y.

AU - Shimamoto, Y.

AU - Fukushima, H.

AU - Yamaguchi, K.

AU - Takatsuki, K.

AU - Matsumoto, M.

AU - Hanada, S.

AU - Uozumi, K.

AU - Utsunomiya, A.

AU - Araki, K.

AU - Ohshiro, I.

PY - 2007/9

Y1 - 2007/9

N2 - Granulocyte colony-stimulating factor (G-CSF)-supported, post-remission chemotherapy (Cx) for adult acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) was evaluated. One hundred and forty-three eligible patients (median age, 41years) including 126 ALL and 17 LBL receiving induction Cx (vincristine, cyclophosphamide, prednisolone [PSL], doxorubicin, L-asparaginase, intrathecal-methotrexate [IT-MTX]) were analyzed. For patients achieving complete response (CR), two courses of post-remission Cx (course A of daunorubicin, cytosine arabinoside, vindesine, PSL plus IT-MTX; course B of mitoxantrone, etoposide, vincristine, PSL plus IT-MTX) with the use of G-CSF were repeated alternately; thereafter, maintenance Cx including MTX and 6-mercaptopurine was given for 2 years. One hundred and nineteen (83%) patients achieved CR, while 14 (10%) died during induction. Among the 119 patients achieving CR, five died in remission, 76 relapsed, and the remaining 38 were alive without disease. The median survival time of the 143 eligible patients was 26 months (95% confidence interval, 19-34). At a median follow-up time of 9 years, the 5-year survival rate was 32% and the 5-year progression-free survival (PFS) rate was 26%. The 5-year survival rate of 36 patients who underwent autologous (n = 20) or allogeneic stem cell transplantation (SCT; n = 16) in the first CR group was 58%. Compared with the authors' previous trials, survival and PFS were markedly improved. In conclusion, G-CSF-supported, intensive post-remission Cx and subsequent SCT are worthy of further investigation for the treatment of adult ALL and LBL.

AB - Granulocyte colony-stimulating factor (G-CSF)-supported, post-remission chemotherapy (Cx) for adult acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) was evaluated. One hundred and forty-three eligible patients (median age, 41years) including 126 ALL and 17 LBL receiving induction Cx (vincristine, cyclophosphamide, prednisolone [PSL], doxorubicin, L-asparaginase, intrathecal-methotrexate [IT-MTX]) were analyzed. For patients achieving complete response (CR), two courses of post-remission Cx (course A of daunorubicin, cytosine arabinoside, vindesine, PSL plus IT-MTX; course B of mitoxantrone, etoposide, vincristine, PSL plus IT-MTX) with the use of G-CSF were repeated alternately; thereafter, maintenance Cx including MTX and 6-mercaptopurine was given for 2 years. One hundred and nineteen (83%) patients achieved CR, while 14 (10%) died during induction. Among the 119 patients achieving CR, five died in remission, 76 relapsed, and the remaining 38 were alive without disease. The median survival time of the 143 eligible patients was 26 months (95% confidence interval, 19-34). At a median follow-up time of 9 years, the 5-year survival rate was 32% and the 5-year progression-free survival (PFS) rate was 26%. The 5-year survival rate of 36 patients who underwent autologous (n = 20) or allogeneic stem cell transplantation (SCT; n = 16) in the first CR group was 58%. Compared with the authors' previous trials, survival and PFS were markedly improved. In conclusion, G-CSF-supported, intensive post-remission Cx and subsequent SCT are worthy of further investigation for the treatment of adult ALL and LBL.

UR - http://www.scopus.com/inward/record.url?scp=34547763840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547763840&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2007.00556.x

DO - 10.1111/j.1349-7006.2007.00556.x

M3 - Article

VL - 98

SP - 1350

EP - 1357

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 9

ER -